Work

A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody-Drug Conjugate Exerted Antitumor Activity in a Pancreatic Cancer Xenograft Model

Year: 2026
Type: article
Abstract: Podocalyxin (PODXL) is a potential diagnostic biomarker and therapeutic target in various tumors. Development of anti-PODXL mAbs has been limited by concerns about potential reactivity with normal tissues. To minimize on-target, off-tumor toxicities and adverse effects, we developed cancer-specific mAbs (CasMabs) against PODXL and demonstrated antitumor efficacy in human tumor xenograft models. In this study, we evaluated humPcMab-60-DXd, an anti-PODXL CasMab conjugated with DXd, a derivative of the topoisomerase I inhibitor exatecan. humPcMab-60-DXd retained cancer-specific reactivity with the pancreatic ductal adenocarcinoma MIA PaCa-2 cell line. Furthermore, humPcMab-60 was internalized into MIA PaCa-2 and inhibited cell proliferation in vitro. In the MIA PaCa-2 xenograft model, humPcMab-60-DXd showed superior antitumor efficacy compared with humPcMab-60. Moreover, humPcMab-60-DXd exhibited dose-dependent antitumor activity without reducing mice body weight. Histological analyses revealed the collapse of the intratumoral structure and a reduction in PODXL expression in the humPcMab-60-DXd-treated xenograft. These results provide the first observation of antitumor efficacy for an anti-PODXL CasMab–drug conjugate, which could facilitate the clinical development of CasMabs for tumor therapy.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7213325698
FWCI:
Cites: 48
Cited by:
Related to: 10